Products
  1. Home
  2. Products
  3. Inhibitors & Activators for IBD Research
Products
Inquiry

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

CDK9-IN-7

Cat. No.: IBDI-435835

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target CDK | Apoptosis
Molecular Weight 547.71
Appearance Solid
SMILES O=C(N(C)C)C1=CC2=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N=C2N1C4CCCC4
Purity 99.81%

Storage & Handling

Shipping Room temperature in continental US. May vary elsewhere.
Storage Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.
! For research use only, not intended for any clinical use.
Copyright © Ace Therapeutics. All rights reserved.